Table 3.

Cox proportional hazards models for the primary composite endpoint of death, coronary heart failure hospitalization, stroke, or MI

	Four-month landmark analysis N=1260		Nine-month landmark analysis N=1057
Variable	HR, 95% CI	P-value	HR, 95% CI	P-value
Model 1
Target arm (high vs low)	1.44, 1.05–1.97	0.02	1.62, 1.09–2.40	0.02
Model 2
Target arm (high vs low)	1.26, 0.89–1.78	0.20	1.44, 0.95–2.18	0.09
Not achieving hemoglobin target	1.46, 1.00–2.13	0.05	1.99, 1.12–3.55	0.02
Model 3
Target arm (high vs low)	1.26, 0.90–1.75	0.18	1.37, 0.89–2.11	0.15
High-dose ESA	1.71, 1.20–2.43	0.003	1.54, 1.00–2.35	0.05
Model 4
Target arm (high vs low)	1.21, 0.85–1.71	0.29	1.28, 0.82–2.00	0.27
Not achieving hemoglobin target	1.17, 0.76–1.79	0.47	1.76, 0.97–3.20	0.06
High-dose ESA	1.60, 1.08–2.38	0.02	1.40, 0.90–2.19	0.13
Model 5	N=1192		N=1016
Target arm (high vs low)	1.17, 0.81–1.68	0.41	1.25, 0.80–1.97	0.33
Not achieving hemoglobin target	1.21, 0.78–1.89	0.39	1.80, 0.97–3.34	0.06
High-dose ESA	1.57, 1.04–2.36	0.03	1.48, 0.94–2.32	0.09
Self-reported hypertension	0.94, 0.48–1.85	0.86	0.66, 0.32–1.37	0.27
Previous CABG	2.44, 1.70–3.49	<0.01	1.75, 1.08–2.86	0.02
Use of IV iron	0.47, 0.12, 1.90	0.29	0.36, 0.05, 2.63	0.32

CABG, coronary artery bypass graft; ESA, erythropoietin-stimulating agent.